Belgian developer Nyxoah said yesterday it raised $20 million (EU €18 million) to support its progress towards eventual CE Mark and FDA approval for its novel neurostimulation based disruptive therapy for patients with obstructive sleep apnea.
The company is developing a lead-free neurostimulator designed to deliver bilateral hypoglossal nerve stimulation to treat moderate to severe OSA patients who have failed conventional therapy with a CPAP machine.
Funding in the round was led by Gilde Healthcare, and joined by SRIW and existing shareholders, with Novallia providing a subordinated loan. Proceeds from the round will fund the company’s go-to-market strategy, including regulatory approvals and the Blast OSA international study.
“Gilde Healthcare’s domain expertise in medtech and sleep will support the management team to achieve Nyxoah’s vision of becoming a leader in OSA therapy. In Western countries alone there are 5 million OSA patients who require treatment but have failed current gold standard therapy. this large unmet need can be addressed by Nyxoah’s bilateral neurostimulation therapy,” co-founder and current CEO Robert Taub said in a press release.
Nyxoah also announced it tapped medtech vet and current LivaNova (NSDQ:LIVN) corporate business development director Enrique Vega as its new CEO, scheduled to take the corner office in September this year.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.